The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions

    loading  Checking for direct PDF access through Ovid

Abstract

The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor β1.

Related Topics

    loading  Loading Related Articles